Delic Holdings Inc. Acquires Complex Biotech Discovery Ventures Ltd.

Delic Holdings Acquires Ketamine Infusion Centers LLC

December 7, 2020

Healthcare Services

Delic Holdings Inc. (DELIC) entered into an agreement to acquire all membership interests of Ketamine Infusion Centers LLC (KIC), an operator of two ketamine infusion clinics in Phoenix, Arizona and Bakersfield, California. The transaction (structured as a reverse triangular merger) expands DELIC's psychedelic wellness platform by adding physical clinic operations and a team of medical professionals, with consideration primarily issued as DELIC subordinate voting shares and contingent milestone shares.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Lucy Scientific Discovery Acquires BlueSky Wellness

September 12, 2023

Consumer Products

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) agreed to acquire BlueSky Wellness Inc. in an all-stock transaction that will add a portfolio of plant-based wellness CPG brands (Keoni, Keoni Sport, Blush Wellness, AMMA Healing) and e-commerce capabilities. BlueSky shareholders will receive 3.5 million Lucy shares plus up-to-five-year EBITDA-based earnouts; Lucy expects the combined transactions with its High Times IP acquisition to add at least $30 million in revenue and $10 million of EBITDA in the first 12 months.

Enveric Biosciences Acquires MagicMed Industries

May 24, 2021

Biotechnology

Enveric Biosciences entered into a definitive all-stock agreement to acquire MagicMed Industries, a Calgary-based biotechnology company focused on psychedelic-derived drug discovery, in an amalgamation that will make MagicMed an indirect wholly owned subsidiary of Enveric. The deal expands Enveric’s pipeline beyond cannabinoids into psychedelic-derived molecules (psilocybin, DMT derivatives, etc.), includes issuance of Enveric common stock and equity awards to MagicMed shareholders, and contemplates leadership changes with Dr. Joseph Tucker named CEO upon closing.

Cannabinoid Biosciences Acquires CannabidiolHemp

November 25, 2019

Consumer Products

Cannabinoid Biosciences, Inc., a California-based biopharmaceutical subsidiary of Kid Castle, has acquired CannabidiolHemp (CannabidiolHemp.net), a CBD quality aggregator and validator. The purchase is the first of multiple planned acquisitions intended to build a vertically integrated CBD distribution and supply-chain business across the United States and Canada.

Blackhawk Growth Corp Acquires Trip Pharma Inc.

October 13, 2020

Healthcare Services

Blackhawk Growth Corp. completed the acquisition of all outstanding shares of Trip Pharma Inc., an Edmonton-based psychedelic development and wellness company led by Dr. Krista Leicht. The transaction was satisfied largely with issuance of common shares to Trip Pharma shareholders and brings Trip Pharma into Blackhawk's existing healthcare/cannabis investment portfolio as it pursues clinical research and a psychiatric research clinic focused on psilocybin-based therapies.